The impact of COVID‐19 on medication reviews in English primary care. An OpenSAFELY‐TPP analysis of 20 million adult electronic health records
Authors:
- The OpenSAFELY CollaborativeTCThe OpenSAFELY Collaborative
- Christopher WoodCWChristopher Wood
- Victoria SpeedVSVictoria Speed
- Louis FisherLFLouis Fisher
- Helen J. CurtisHCHelen J. Curtis
- Andrea L. SchafferASAndrea L. Schaffer
- Alex J. WalkerAWAlex J. Walker
- Richard CrokerRCRichard Croker
- Andrew D. BrownABAndrew D. Brown
- Christine CunninghamCCChristine Cunningham
- William J. HulmeWHWilliam J. Hulme
- Colm D. AndrewsCAColm D. Andrews
Open Access
- 26 March 2024
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 90 (7) , 1600-1614
Abstract
Aims: The COVID‐19 pandemic caused significant disruption to routine activity in primary care. Medication reviews are an important primary care activity ensuring safety and appropriateness of prescribing. A disruption could have significant negative implications for patient care. Using routinely collected data, our aim was first to describe codes used to record medication review activity and then to report the impact of COVID‐19 on the rates of medication reviews.Methods: With the approval of NHS England, we conducted a cohort study of 20 million adult patient records in general practice, in‐situ using the OpenSAFELY platform. For each month, between April 2019 and March 2022, we report the percentage of patients with a medication review coded monthly and in the previous 12 months with breakdowns by regional, clinical and demographic subgroups and those prescribed high‐risk medications.Results: In April 2019, 32.3% of patients had a medication review coded in the previous 12 months. During the first COVID‐19 lockdown, monthly activity decreased (−21.1% April 2020), but the 12‐month rate was not substantially impacted (−10.5% March 2021). The rate of structured medication review in the last 12 months reached 2.9% by March 2022, with higher percentages in high‐risk groups (care home residents 34.1%, age 90+ years 13.1%, high‐risk medications 10.2%). The most used medication review code was Medication review done 314530002 (59.5%).Conclusions: There was a substantial reduction in the monthly rate of medication reviews during the pandemic but rates recovered by the end of the study period. Structured medication reviews were prioritized for high‐risk patients.Keywords
All Related Versions
Funding Information
- Health Data Research UK (2021.0157, HDRUK2021.000)
- Medical Research Council (MR/V015737/1, MR/W016729/1, MC_PC_20059)
- Wellcome Trust (222097/Z/20/Z)
- UK Research and Innovation (MC_PC_20058)
This publication has 21 references indexed in Scilit:
- Frequency and impact of medication reviews for people aged 65 years or above in UK primary care: an observational study using electronic health recordsBMC Geriatrics, 2023
- Changes in medication safety indicators in England throughout the covid-19 pandemic using OpenSAFELY: population based, retrospective cohort study of 57 million patients using federated analyticsBMJ Medicine, 2023
- Eleven key measures for monitoring general practice clinical activity during COVID-19 using federated analytics on 48 million adults’ primary care records through OpenSAFELYmedRxiv, 2022
- OpenSAFELY: Representativeness of electronic health record platform OpenSAFELY-TPP data compared to the population of EnglandWellcome Open Research, 2022
- Clinical coding of long COVID in English primary care: a federated analysis of 58 million patient records in situ using OpenSAFELYBritish Journal of General Practice, 2021
- Indirect acute effects of the COVID-19 pandemic on physical and mental health in the UK: a population-based studyThe Lancet Digital Health, 2021
- Impact of Electronic Health Record Interface Design on Unsafe Prescribing of Ciclosporin, Tacrolimus, and Diltiazem: Cohort Study in English National Health Service Primary CareJournal of Medical Internet Research, 2020
- Pharmacist-led medication review in community settings: An overview of systematic reviewsResearch in Social and Administrative Pharmacy, 2017
- BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugsRheumatology, 2017
- Quality of recording of diabetes in the UK: how does the GP's method of coding clinical data affect incidence estimates? Cross-sectional study using the CPRD databaseBMJ Open, 2017